Bernhard Hampl, PH.D.

CEO Advisory Board Member

Bernhard Hampl, Ph.D. is the former Co-Chairman of the board of directors of Softbox (GPP II) and Cytovance (GPP I).

Dr. Hampl was the President and CEO of Eon Labs.  Under his leadership, sales grew from $20 million to $435 million without acquisitions.  During the four-year period from 2000 to 2004, Eon had the most Abbreviated New Drug Applications (“ANDAs”) approved among all US generic companies.  Shares of Eon Labs appreciated 350% from the 2001 IPO until the 2005 acquisition by Novartis for $2.8 billion.  After the acquisition, he became the CEO of the Sandoz Division of Novartis.

He is also currently Executive Chairman of APP/Fresenius Kabi.  Dr. Hampl was previously an executive board member for the Generic Pharmaceutical Association.

He received his Ph.D. from the Ludwig Maximilian University of Munich in Germany.

CEO Advisory Board members are consultants and are not exclusive to Great Point.  Amounts paid to CEO Advisory Board members and related expenses are born by fund or portfolio company investors.